Podcasts about tki

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

“All of these TKIs [tyrosine kinase inhibitors] inhibit BCR-ABL1 in some way, shape, or form. When BCR-ABL1 is mutated, it has uncontrolled tyrosine kinase activity, leading to rapid cell proliferation. When we then inhibit that BCR-ABL1 that's been mutated, we disrupt this abnormal signaling pathway that drives CML [chronic myeloid leukemia] cell proliferation and survival, ultimately leading to decreased cancer cell growth, increased apoptosis or cell death, and potentially inducing a disease remission,” Samantha Maples, PharmD, BCOP, clinical pharmacy specialist supervisor for hematology and cellular therapy at Allegheny Health Network in Pittsburgh, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the BCR-ABL1 inhibitor drug class.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0   Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by September 5, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: Learner will report an increase in knowledge related to the use of BCR-ABL1 inhibitors in the treatment of CML. Episode Notes   Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 322: Nursing Strategies to Reduce Readmission Rates for Patients With Cancer Episode 215: Navigate Updates in Oral Adherence to Cancer Therapies ONS Voice articles: Adherence to Oral Anticancer Medication Combination Therapy Shows Promise for Chronic Myeloid Leukemia The Case of the Medication Modification The Case of the Safety Session ONS course: Safe Handling Basics Clinical Journal of Oncology Nursing articles: Targeted Drug Therapies: Beyond Blood Counts and Chemistries Oncology Nursing Forum articles: Adherence and Coping Strategies in Outpatients With Chronic Myeloid Leukemia Receiving Oral Tyrosine Kinase Inhibitors Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors Other ONS resources: Biomarker Database Financial Toxicity Huddle Card Tyrosine Kinase Inhibitors Huddle Card Oral Anticancer Medication Care Compass: Resources for Interprofessional Navigation Oral Anticancer Medication Learning Library National Comprehensive Cancer Network National Comprehensive Cancer Network patient resources To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode  “The IRIS study led to the approval of the BCR-ABL1 and TKI, imatinib, for CML in 2001 and completely changed the landscape of CML treatment. Then came the second-generation BCR-ABL1 TKIs: dasatinib in 2006, quickly followed by nilotinib in 2007. Thereafter came our second-generation, bosutinib, and our first approved third-generation TKI, ponatinib, both in 2012, which was a huge milestone as ponatinib overcomes resistance to the T315 I mutation, which no previously approved TKIs worked against.” TS 2:16 “The newest approved TKI, asciminib, is an allosteric inhibitor that binds to a different pocket on the BCR-ABL kinase via allosteric binding to the ABL myristoyl pocket. It's what's called a STAMP inhibitor, where STAMP stands for ‘specifically targeting the ABL myristoyl pocket.' And while all the TKIs target the BCR-ABL1 binding site, they can also inhibit different off-target kinases. And these differences in off-target inhibition are responsible for some of the different toxicities we see among the TKIs.” TS 4:51 “As a class, common toxicities include nausea; vomiting; diarrhea; cardiac toxicities, including cardiac arrhythmias and congestive heart failure; metabolic abnormalities such as hypercholesterolemia and hypertriglyceridemia; nephrotoxicity; hepatic toxicity; hemorrhaging and bleeding; as well as cytopenia. Individually, some of these agents are more likely to cause certain side effects compared to others, and there are unique toxicities associated with certain TKIs.” TS 8:10 “We've moved to using preemptive loperamide [in our clinic] for the first three days of starting treatment, because it's really hard to get patients to continue to take a medication if they have such severe diarrhea that they end up in the hospital or they're unable to leave their house. A lot of times, we will proactively give patients antiemetics and loperamide to help with the nausea, vomiting, and diarrhea. And then we can back off to an as-needed basis once they've been established on treatment. We can also use medications to help manage long-term complications that can require supportive care, such as statin therapy for high cholesterol, levothyroxine for hypothyroidism, anticoagulants for any venous thromboembolism, and antihypertensive medications for managing any new or worsening high blood pressure.” TS 12:44 “We are continually seeing these agents expand their indications to different lines of therapy, as well as more TKIs being approved for acute lymphoblastic leukemia. For example, asciminib just got approved in the frontline setting within the last year, whereas previously it was only approved in relapsed refractory setting. Last year, imatinib was the first BCR-ABL1 TKI to come out with a commercially supplied suspension option as well, which is huge in the pediatric space and [for] our adult patients who are unable to swallow tablets for other clinical reasons.” TS 21:22 “There is more information being published on the safe discontinuation of these medications with treatment-free remissions, and more information is coming out about who would be eligible and who can have the option to stop these treatments instead of having a lifelong chronic condition requiring continuous treatment. We're seeing more patients in clinical practice be able to stop BCR-ABL1 treatment, which has been a great development in CML.” TS 25:29

Its time to rest and recupe, but in the middle of the tower?Buy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Welcome back to the Oncology Brothers podcast! In this episode, Drs. Rohit & Rahul Gosain are joined by Dr. Joshua Sabari from the NYU Langone Cancer Center to discuss the exciting recent approval of Zongertinib, the first oral TKI for HER2-positive lung cancer. We dived deep into the prevalence of HER2 mutations in non-small cell lung cancer, the study design and findings from the Beamion LUNG-1 trial, and the implications of this new therapy in clinical practice. Dr. Sabari shared insights on the efficacy of Zongertinib, including impressive response rates and progression-free survival data, as well as its side effect profile compared to other treatments like trastuzumab deruxtecan (T-DXd). Key topics covered in this episode: •⁠  ⁠Overview of HER2 mutations in lung cancer •⁠  ⁠Study design and results of the Beamion LUNG-1 •⁠  ⁠Comparison of Zongertinib and T-DXd in treatment settings •⁠  ⁠Management of common side effects associated with Zongertinib •⁠  ⁠Future directions for HER2-targeted therapies Join us for this informative discussion as we explore the latest advancements in lung cancer treatment and what they mean for patients and clinicians alike. Don't forget to subscribe for more episodes on new approvals, side effect management, and practice-changing data in oncology! Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/

Battle in the Amplitheater of Tennison Tower rages on!Buy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Jakso pureutuu teemaan “Mittaa, ymmärrä, johda”. Heli Järnefelt (TyhyTeko-hankkeen projektipäällikkö, Xamk) juttelee Jaakko Heikkilän (TKI-asiantuntija, Xamk) kanssa siitä, miten työhyvinvointia voidaan kehittää mitatun tiedon avulla. Keskustelussa avataan fysiologisten mittausten (esim. lihasaktiivisuus, istumisen ja seisomisen suhde, askelmäärät ) merkitystä arjen päätöksissä ja johtamisessa, pohditaan fyysisen aktiivisuuden “paradoksia” työssä sekä sitä, miten objektiivinen data ja työntekijän kokemus yhdistetään ihmislähtöiseksi johtamiseksi. Jaksossa kuullaan käytännön vinkkejä alkuun pääsemiseen – pienistä askeleista ja älykellojen perusmittareista tulosten avoimeen käsittelyyn – jotta hyvinvointi ja tuottavuus kulkisivat käsi kädessä. Jakson tekijät: Käsikirjoitus: Heli Järnefelt ja Jaakko Heikkilä, Kaakkois-Suomen ammattikorkeakoulu Keskustelijat: Heli Järnefelt, projektipäällikkö sekä Jaakko Heikkilä, TKI-asiantuntija, Kaakkois-Suomen ammattikorkeakoulu Editointi: Jonne Hirvonen, Kaakkois-Suomen ammattikorkeakoulu TyhyTeko-intro, -jingle sekä -outro: Riitta Koivisto, Jyväskylän ammattikorkeakoulu TyhyTeko-podcast tuotetaan osana TyhyTeko - Työhyvinvointia ja tuottavuutta marata-alan ammattilaisille tekoälyn ja robotiikan avulla -hanketta. TyhyTeko-hanke on Euroopan unionin osarahoittama hanke, jota toteuttamassa ovat Jyväskylän, Kaakkois-Suomen, Lapin, Savonia-, Seinäjoen ja Tampereen ammattikorkeakoulut. Hankkeen tarkoituksena on marata-alan ammattilaisten työhyvinvoinnin ja tuottavuuden parantaminen sekä työn tehostaminen tekoälyn ja robotiikan käyttöönoton avulla. Jakson lähteet: https://www.jamk.fi/fi/media/43256 Jakson tekstivastine: https://www.jamk.fi/fi/media/43255 Lisätiedot hankkeesta www.jamk.fi/tyhyteko

A panel of hematology leaders discusses the latest in ALL and T-cell ALL therapy, including TKI+blina combinations, venetoclax strategies, and the emerging role of CD7 CAR T-cell therapies in reshaping treatment paradigms.

The party stalks and gets the jump on the tower...Buy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in treating HER-mutated advanced NSCLC.

Deception, Diplomacy or Intimidation? Which is best for an Interrigation that bars violence...Buy Fantasy Grounds Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Lady Mialari Docur's school for girls has many interesting secrets...Buy Fantasy Grounds Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Please visit answersincme.com/KTK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastrointestinal cancers discusses strategies for treatment of patients with colorectal cancer using tyrosine kinase inhibitors. Upon completion of this activity, participants should be better able to: Identify patients with metastatic colorectal cancer (mCRC) who are suitable for tyrosine kinase inhibitor (TKI) treatment; Outline practical, patient-centered strategies to maximize quality of life in patients receiving later-line TKI treatment for mCRC; and Review approaches to manage adverse events associated with later-line TKI treatment for mCRC.

Fighting tiger people spellcaSTERS TAKES A LITTLE FAITH?Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Following the FDA approval of taletrectinib (Ibtrozi) for patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC), CancerNetwork® spoke with Jorge Nieva, MD, about how this regulatory decision may impact the treatment paradigm for this disease. The approval was supported by findings from the phase 2 TRUST-I trial (NCT04395677) and the phase 2 TRUST-II trial (NCT04919811). The total efficacy population included 157 patients who had no prior treatment with a ROS1 tyrosine kinase inhibitor (TKI) and 113 who were previously treated with a ROS1 TKI. Topline results showed an objective response rate (ORR) of 90% (95% CI, 83%-95%) in TRUST-I and 85% (95% CI, 73%-93%) in TRUST-II among patients who had no prior treatment. Of those with pretreated disease, the respective ORRs were 52% (95% CI, 39%-64%) and 62% (95% CI, 46%-75%) in each study population. According to Nieva, an associate professor of clinical medicine at the Keck School of Medicine of the University of Southern California, taletrectinib may offer advantages over other therapies in the ROS1-positive metastatic NSCLC space based on its improved central nervous system (CNS) toxicity profile and “excellent” response and progression-free survival data. He stated that taletrectinib would become the go-to first-line agent in his practice. Additionally, he discussed strategies for mitigating toxicities related to taletrectinib such as nausea and diarrhea, and highlighted the need for additional research to improve immunotherapy options in NSCLC.  “I'm very happy that we have choices for patients, and I'm very happy that we have such a wide variety of drugs, but we still need to do better, and we need to find better ways of using these agents because they're still not cures for the majority of patients,” Nieva stated. “While these drugs can be helpful at debulking tumors, we still need to do a lot more work [to do] on making this a disease of the past for those patients who have it.” Reference FDA approves taletrectinib for ROS1-positive non-small cell lung cancer. News release. FDA. June 11, 2025. Accessed July 8, 2025. https://tinyurl.com/yc4f379m

2 Commoners cowering in a corner, concern our cunning party and turn out to be a little too clever until...Products through Our Affiliate link below. http://affiliates.fantasygrounds.com/370352/15958http://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)http://www.rollmonger.comhttp://www.TeeSpring.com/RollMongershttp://www.Patreon.com/RollMongershttps://podcast.feedspot.com/pathfinder_roleplaying_game_podcasts/Music: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (https://incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audiohttps://Tabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongers Thank You For your needed Support! https://www.RollMonger.com https://www.TeeSpring.com/RollMongers for Merch! https://www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

In this JCO Article Insights episode, host Peter Li summarizes "Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST" by Pérol et al, published April 03, 2025, followed by an interview with first author, Dr Maurice Pérol. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Peter Li: Welcome to this episode of JCO Article Insights. I am Dr. Peter Li, JCO's editorial fellow, and today I am joined by Dr. Maurice Pérol on “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” by Pérol et al. At the time of this recording, our guest has disclosures that will be linked in the transcript. Before we start our interview, I want to give our listeners a quick summary of the TRUST study. For those tuning in, the TRUST study is a phase II, single-arm, open-label, nonrandomized, multicenter trial looking at the efficacy and safety of a novel, next-generation ROS1 TKI, taletrectinib, in advanced ROS1-mutated non–small cell lung cancer. While a relatively rare mutation, the prevalence of ROS1 mutations ranges from 0.9% to 2.6% of patients, with a third of patients presenting with brain mets at diagnosis.Current FDA-approved therapies include crizotinib, entrectinib, and repotrectinib, which have varying degrees of efficacy, in-coming with trade-offs in CNS penetrance and safety with newer generations, particularly in the realm of neurological side effects, highlighting an unmet need in this arena. A total of 273 patients with advanced non–small cell lung cancer with confirmed ROS1 mutation were recruited for this study. 160 patients were TKI-naive, while 113 were TKI-experienced with either crizotinib or entrectinib. Patients with asymptomatic brain mets were also allowed to enroll. In the TKI-naive arm, the median age was 57, with 91% of patients having stage IV disease, 20% having no more than one cycle of chemo, and 23% having brain mets at baseline. In the TKI-experienced arm, the median age was 53, with 97% having stage IV disease, 37% having received prior chemo, and about 50% having brain mets. Furthermore, about 10% of the study population had received entrectinib, while more than 90% had received crizotinib. About 10% had a known G2032R acquired resistance mutation. Taletrectinib was dosed at 600 mg daily until disease progression or unacceptable toxicities. The primary endpoint was overall response rate, with secondary endpoints being disease control rate, duration of response, time to response, and progression-free survival. For those with brain mets, intracranial overall response rate and disease control rate were also assessed. Median follow-up time was about 21 months in both cohorts. In the TKI-naive cohort, the overall response rate was 89%, with 8 patients achieving a complete response. Disease control rate was 95%, with a median duration of response of 44.2 months. Time to treatment response was about 1.5 months. Median progression-free survival was 45.6 months, with 52.6% not having progressed at 3 years. While overall survival data were immature, 66% of patients were still alive at 3 years. In the pretreated cohort, overall response rate was 56%, with 5 patients achieving a complete response. Overall response rate was 53% for those who were crizotinib-pretreated and 80% for the entrectinib-pretreated patients. Disease control rate was 88%, and median duration of response was about 16.5 months. Time to treatment response was also 1.5 months, and median progression-free survival was 9.7 months. Median overall survival was not reached, but 77.5% of patients were still alive at 1 year. Responses were consistently seen across subgroup analyses. 17 TKI-naive and 32 TKI-pretreated patients had measurable brain mets. In the TKI-naive arm, intracranial overall response rate was 77%. Disease control rate was 88%, and duration of response was 15 months. In the TKI-pretreated arm, intracranial overall response was 66%, with one patient achieving complete response. The disease control rate was 94%, and duration of response was about a year. For the 13 patients who had a known G2032R mutation, a 62% response rate was noted. Most common treatment-related side effects were AST/ALT elevation, nausea, and vomiting, with most being grade 1 or 2. Most common neurological side effects were dizziness, dysgeusia, and headache. Again, most were grade 1. QTc prolongation is another important adverse event to note, occurring in about 18% of all patients. Discontinuation rate from treatment was only 7%. There were three treatment-related deaths in this study: one from hepatic failure, one from pneumonia in the naive arm, and one from liver dysfunction in the pretreated arm. Dr. Peter Li: Maurice, thank you so much for joining us today to talk about your paper. Would you mind just giving yourself a brief introduction to the listeners out there of who you are? Dr. Maurice Pérol: So, my name is Maurice Perol. I'm a thoracic oncologist working in the Cancer Center of Lyon in France. And I'm involved in clinical research in thoracic oncology. I've been involved for many years now. Dr. Peter Li: Okay. And for listeners out there, don't forget, he's also the primary author of the paper that we just talked about. So, Maurice, let's begin. Can you tell our listeners what is the significance of your study? Dr. Maurice Pérol: Well, the results of these two large phase II studies - TRUST-I, which has been conducted in China, and TRUST-II, which was a global, worldwide phase II study - so, the results place taletrectinib as the TKI with the most favorable efficacy-tolerability ratio of the available ROS1-targeting TKIs, especially in frontline therapy. And this is based on the response rate, which was very impressive, the CNS penetration with a great CNS activity, the duration of response with a compelling 45 months median PFS in frontline setting. The level of activity in pretreated patients after crizotinib or entrectinib was also impressive and similar to that of repotrectinib, for example, but with a more favorable neurological tolerance profile. The toxicity is mainly represented with grade 1 or 2 transaminase elevation, but without clinical symptoms, and GI toxicity, but mainly grade 1 and 2. The neurological toxicity is low, especially for dizziness, showing that taletrectinib spares TrKB in a large part. And finally, there is also a decrease in toxicity over time, especially for GI toxicity and liver toxicities, which allows a very long and a prolonged administration, which is very important in this setting. Dr. Peter Li: These are all excellent points. Can you tell the listeners if there are any limitations that we should be concerned about, about this study? Dr. Maurice Pérol: Sure. This data comes from single-arm phase II studies. So, this is not comparative data. And a phase III trial, which compares taletrectinib to crizotinib, is ongoing to evaluate the superiority of taletrectinib over the standard of care. Another limitation comes from the lack of systematic brain imaging at each tumor evaluation in patients without brain metastases at baseline, not allowing to assess the intracranial PFS in all patients, and which did not allow us to assess the CNS protective issue from taletrectinib, especially in patients without brain metastases at baseline. Dr. Peter Li: Another question that I have is, with this novel TKI now available, how would you recommend the sequencing of these drugs? Would you start with someone on an alternate TKI and then reserve taletrectinib second line or later? Or would you use it upfront? Or does it depend? Dr. Maurice Pérol: Well, it is a very important question, as we have now different available TKIs. Looking at the efficacy-toxicity balance, I would strongly favor the use of taletrectinib in frontline setting, in first line. The response rate, the CNS activity, the duration of response with a very compelling 45 months median PFS, and moreover, the good tolerance profile over time are strong arguments in favor of giving taletrectinib in frontline. Generally speaking, the use of the most active agent as frontline treatment in lung cancer depending on an oncogenic addiction is probably the best way to improve the patient's outcome. This is true for patients with EGFR mutation, for patients with ALK fusions, and this is probably also true for patients with ROS1 fusion. So, I would probably argue in favor of a frontline use of taletrectinib. Dr. Peter Li: Listeners are going to ask, well, if you use taletrectinib upfront, then what are you going to use second line once they progress? Dr. Maurice Pérol: Well, we have some new compounds which are under development today. For example, the NVL-520, which is a very interesting compound, which seems also to be active in case of resistance mutation. But I do think that we have to use the best-in-class TKI in frontline because, you know, the extension of PFS after acquired resistance you can obtain with a second-line TKI is always shorter than the benefit you can obtain by using the most active agent in frontline. And this is true for the majority of oncogenic addiction in lung cancer. Dr. Peter Li: That makes sense. I also noticed that cognitive impairment wasn't listed in the safety table. Is that not an issue that you've observed at all with taletrectinib, or is it still an issue but less so because, like you mentioned earlier, because of its higher selectivity? Dr. Maurice Pérol: Well, this is a good question because we have some ROS1-targeting TKIs like repotrectinib, entrectinib, and even lorlatinib, with some neurological adverse events and some cognitive issues. Taletrectinib is a very selective ROS1-targeting TKI, and it spares very well the TrKB, for example, explaining that we did not observe any cognitive impairment with taletrectinib in the TRUST study, showing also with the low level of other neurological adverse events, dizziness, dysgeusia, for example, the high selectivity of the compound and the preservation of TrKB. So, this is very important when you consider the long duration of treatment in those patients with ROS1 fusion. If you have to take a drug for more than 2, 3, or 4 years, of course, the neurological adverse events are very important, and they can clearly impair the quality of life. So, this is a very important point, the very low level of neurological toxicity of taletrectinib. Dr. Peter Li: And I think that goes to say why you would favor using it frontline as well compared to entrectinib or repotrectinib. Last question that we have for you is: well, what's next? You mentioned there's a phase III trial comparing it to crizotinib. I think one of the questions that a lot of us would have is: why not compare it to one of the newer agents as a comparator arm? Dr. Maurice Pérol: Well, this is a good question. Crizotinib remains the standard of care in many countries for ROS1-positive advanced non–small cell lung cancer outside of the US, especially in Europe, and in particular in patients who do not have brain metastases at diagnosis. Entrectinib has a better CNS penetration, but it did not achieve a better PFS than crizotinib in phase I/II trials, and clearly, it has a less favorable tolerance profile with weight gain, edema, and neurological adverse events. Repotrectinib has overall a level of activity which seems close to that of taletrectinib. So, it makes it difficult to consider a comparative trial that would, for example, test taletrectinib in comparison with repotrectinib because this kind of study would need a very large number of patients and a very late readout. Considering if you have a median PFS of more than 3 or 4 years, it would be very difficult to have results in before 4-5 years. So, from a pragmatic point of view, the comparison of taletrectinib to crizotinib is probably the best way to evaluate in a phase III setting the level of activity of taletrectinib, especially in the CNS, because this study will probably allow us to assess the CNS protective effect of the compound for patients without brain metastates at baseline. So, I think probably it's a pragmatic study that will allow us to confirm the high level of activity and the good tolerance profile of taletrectinib. Dr. Peter Li: Well, thank you, Maurice, so much for speaking about the JCO article, “Taletrectinib in ROS1-Mutated Non–Small Cell Lung Cancer: TRUST,” and for all your valuable input today. Thank you for listening to JCO Article Insights. Please come back for more interviews and article summaries, and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

To Holy Damage Or Not to Holy Damage, Muros & Karom are out of the question.Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity" / Tem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsTem OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Uploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

Not 1 but 2 Ghosts? Hey dont they look awfully familair too?Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity" / Temp OUTRO:The Heaven and Hell Orchestra - Mephistopolis - 09 - The Bell (Hells Bells)Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Arriving at the Long roads coffee house the party, WAIT THERES COFFEE!!Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Dr. John Sweetenham shares highlights from Day 3 of the 2025 ASCO Annual Meeting, including new research for the treatment of advanced renal cell carcinoma and 2 studies on novel approaches in non-small cell lung cancer. Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 3 of the 2025 ASCO Annual Meeting. Today's selection features studies addressing the treatment of advanced renal cell carcinoma and 2 studies exploring novel approaches in non-small cell lung cancer. My disclosures are available in the transcript of this episode. The first abstract is number 4505. This study, led by Dr. Toni Choueiri of the Dana-Farber Cancer Institute, describes the final analysis of the CheckMate 214 trial, which compared the combination of nivolumab and ipilimumab with sunitinib for the first-line treatment of advanced renal cell carcinoma. The ipi-nivo combination is approved for the frontline treatment of intermediate and poor-risk advanced renal cell carcinoma based on the primary analysis of the CheckMate 214 trial, which demonstrated a higher response rate and longer overall survival compared with sunitinib. Today's presentation provided the final safety and efficacy results for the trial with long-term follow-up of more than 9 years.  The intent-to-treat (ITT) population in this trial comprised 550 patients randomized to nivo and ipi versus 546 who received sunitinib. The final analysis showed sustained long-term benefit for the combination therapy. Patients given nivolumab plus ipi had a 29% reduction in the risk for death compared with sunitinib. For patients with intermediate or poor-risk disease, there was a 31% reduction in the risk of death.   The probability of remaining in response through 8 years was more than doubled with nivolumab plus ipilimumab versus sunitinib in the ITT population at 48% versus 19%, and in the intermediate and poor-risk population at 50% versus 23%. The other important observation is that patients with favorable-risk disease appeared to have a 20% reduction in the risk for death at 9 years and more durable responses. This suggests a possible delayed benefit for ipi and nivo in this group since these differences were not seen in the earlier analysis.   No new safety signals emerged with longer follow-up, and the results confirm the use of ipi and nivo as a standard front-line combination therapy in this disease. Since this combination has been in widespread use for some years, the results are not surprising although the subgroup analysis suggesting benefit in favorable-risk patients is likely to inform practice in the future.   Today's second abstract is number is 8506, which was presented by Dr. Tony Mok from the Chinese University of Hong Kong, describing results from the phase 3 HERTHENA-Lung02 trial. This trial compared the antibody-drug conjugate patritumab deruxtecan with platinum-based chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer following a third-generation tyrosine kinase inhibitor (TKI).  Patritumab deruxtecan, also known as HER3-DXd, comprises a fully human anti-HER3 IgG3 monoclonal antibody conjugated to a topoisomerase 1 inhibitor payload, and showed activity in a previous phase 2 trial in patients relapsing after EGFR TKI and chemotherapy.   In this phase 3 study, this agent was compared with platinum-based chemotherapy in eligible patients with an EGFR-activating mutation who had previously received 1 or 2 EGFR TKIs, at least one of which was a third-generation drug, with relapse or progression after this therapy. Five hundred and eighty-six patients were enrolled, with progression-free survival as the primary endpoint.  The primary analysis showed a 9-month progression-free survival of 29% for the experimental arm compared with 19% for platinum-based chemotherapy, for a hazard ratio of 0.77 and a P value of 0.011. With higher progression-free survival rates at 6 months and 12 months, HER3-DXd also had a better objective response rate (35.2% versus 25.3%) compared with platinum-based chemotherapy (PBC), and HER3-DXd also extended intracranial progression-free survival compared with PBC in patients with brain metastases, with a hazard ratio of 0.75. Grade 3 or more treatment-related adverse events occurred in 73% of patients treated with HER3-DXd and 57% of patients who received PBC. HER3-DXd had a higher rate of grade or more 3 thrombocytopenia, and drug-related interstitial lung disease occurred in 5% of patients in the HER3-DXd arm.   The follow-up will need more time to mature since no overall survival data are currently available, but definitely an agent to watch with interest. Moving on to today's final abstract, 8500, was presented by Dr. Pasi Jänne from the Dana-Farber Cancer Institute, describing results from the phase 2 portion of the KRYSTAL-7 study. This study is exploring the use of a potent KRAS inhibitor, adagrasib, in combination with pembrolizumab in patients with advanced or metastatic KRASG12C- mutated non-small cell lung cancer.  Adagrasib has already received accelerated approval in the U.S. for previously treated locally advanced or metastatic NSCLC with a KRASG12C mutation. A previous report from the KRYSTAL-7 study demonstrated encouraging activity in combination with pembrolizumab in the frontline setting for this patient group who also had more than 50% expression of PD-L1. The presentation today described efficacy and safety data for this drug combination across all PD-L1 expression levels.  One hundred and forty-nine patients with a median age of 67 years were treated with the combination, 104 of whom had PD-L1 expression level results available, representing the so-called biomarker population in this trial. The overall response rate for the entire study population was 44%. In the biomarker population, the overall response rate ranged from 36% in those with less than 1% PD-L1 expression to 61% for those with more than 50% expression. For all patients, the median response duration was just over 26 months, and the median progression-free and overall survival rates were 11 and 18.3 months respectively.    For the biomarker population, the median progression-free and overall survival were highest in those patients with more than 50% PD-L1. No new safety issues emerged from this analysis; the most frequent toxicities were nausea, diarrhea, and increases in transaminases. Immune-related toxicities included pneumonitis, hypothyroidism, and hepatitis. These are important results and the results of the phase 3 portion of KRYSTAL-7, which compares first-line therapy with adagrasib plus pembro versus pembro alone in the KRASG12C mutated/PD-L1 more than 50% group, will be informative. For those patients with lower levels of PD-L1 expression, the authors suggest that the treatment escalation may be beneficial, possibly including the addition of chemotherapy.  That concludes today's report. Thanks for listening and I hope you will join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speaker:    Dr. John Sweetenham    Follow ASCO on social media:     @ASCO on Twitter    @ASCO on Bluesky    ASCO on Facebook    ASCO on LinkedIn     Disclosures:   Dr. John Sweetenham:    No relationships to disclose

What? now the ice demon can fly? Muros cant seem to get in a hit?Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe GibsonA Huge THANK YOU! To Our Patreon Supporters: "GrooveLord" & "ExploShawn" Matt Kenney, Daniel Harris, Allen Cooper Jr. Jered Mercer, "NarkMaul" Stephen Cahill (www.Patreon.com/RollMongers)www.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/pathfinder-2e-age-of-ashes-the-elven-portal-podcast--4189253/support.

Next-generation anti-VEGF agents are designed for durability. But does that actually change the rate at which they're administered? David Miller, MD, joins us to review a pair of ARVO 2025 presentations that examined his clinic's real-world administration patterns for bevacizumab (Avastin, Genentech), faricimab (Vabysmo, Genentech/Roche), and high-dose aflibercept (Eylea HD, Regeneron). What were the differences—and did they really matter?  Also, Robert Wang, MD, helped us understand the state of play in the TKI pipeline as he shared data from the phase 2b ODYSSEY study. What are the latest data on CLX-AX (Clearside Biomedcial)? And where does it stack up against the other TKIs in the pipeline? Stick with us to find out. 

Listen in as Jonathan A. Bernstein, MD, and Ryan Haumschild, PharmD, MS, MBA, CPEL, discuss how to manage the multidisciplinary care of patients with systemic mastocytosis (SM) from both the allergy/immunology and pharmacy perspective, including:Strategies to better identify patients presenting with features of SM to facilitate timely diagnosisCurrent guideline-recommended treatment approachesEmerging data on new targeted agents for SMPharmacist-led strategies to help patients achieve better outcomes (e.g., specialist referral, polypharmacy counseling, and anaphylaxis education)PresentersJonathan A. Bernstein, MDProfessor of MedicineDivision of Rheumatology, Allergy and ImmunologyDepartment of Internal MedicineUniversity of Cincinnati College of MedicinePartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center, LLCCincinnati, OhioRyan Haumschild, PharmD, MS, MBA, CPELVice President of Pharmacy, AmbulatoryEmory HealthcareWinship Cancer InstituteAtlanta, GeorgiaFull link to program page:https://bit.ly/3HcA8z2

A Summoned Ice Demon is queit the combatant for the party, hope it doesnt start casting its spells too!Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe Gibsonwww.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/age-of-ashes-the-elven-portal-podcast--4189253/support.

“The signaling and that binding of the MET and the HGF help, in a downstream way, lead to cell proliferation, cell motility, survival, angiogenesis, and also invasion—so all of those key cancer hallmarks. And because of it being on an epithelial cell, it's a really good marker because it's found in many, many different types of cancers, so it makes it what we call kind of a nice actionable mutation,” ONS member Marianne Davies, DNP, ACNP, AOCNP®, FAAN, senior oncology nurse practitioner at Yale Comprehensive Cancer Center in New Haven, CT, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the MET inhibitor drug class. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 9, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to MET inhibitors. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 330: Stay Up to Date on Safe Handling of Hazardous Drugs ONS Voice articles: Oncology Drug Reference Sheet: Amivantamab-Vmjw Oncology Drug Reference Sheet: Cabozantinib Oncology Drug Reference Sheet: Capmatinib Oncology Drug Reference Sheet: Tepotinib Predictive and Diagnostic Biomarkers: Identifying Variants Helps Providers Tailor Cancer Surveillance Plans and Treatment Selection ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Safe Handling of Hazardous Drugs (fourth edition) Telephone Triage for Oncology Nurses (third edition) ONS courses: Safe Handling Basics ONS Biomarker Database ONS Huddle Cards: Monoclonal Antibodies Targeted Therapy ONS Oral Anticancer Medication Learning Library ONS Oral Anticancer Medication Toolkit ONS and NCODA Oral Anticancer Medication Compass Oral Chemotherapy Education Sheets IV Chemotherapy Education Sheets Drugs@FDA To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “The MET receptor was actually identified back in 1984. And it was actually identified as an oncogene in osteosarcoma. And so basically what that MET receptor does—it's a tyrosine kinase pathway, and the ligand that it attaches to is something called HGF/SF. That's hepatocyte growth factor/scatter factor. And so this MET pathway tyrosine kinase pathway is really important in tumor cell growth and migration. And it's expressed specifically on epithelial cells, so that's going to really help us in identifying how it can be a pathway for cancer treatments.” TS 1:35 “But in the particular classes, there kind of are some unique things that are with these MET inhibitors. For example, crizotinib, we found early on, causes some vision changes. Patients would report things like floaters or a little bit of blurry vision. For the capmatinib, things like elevation of amylase and lipase, fluid retention and bloating, and hypersensitivity reactions and photosensitivity.” TS 7:36 “Other things to teach for the TKI is the self-management strategies in terms of nausea management and dietary changes for the risk of peripheral edema. Having them do things like maybe doing daily weights, or at least weights every other day, and sometimes doing limb measurements so it can help us really quantify the amount of fluid retention they have. And then from a nursing perspective, meeting with these patients, is to do really good skin inspection. When people have peripheral edema, they're at risk for skin breakdown, and that can lead obviously to infection.” TS 16:06 “The biggest [misconception] is that people assume that all MET mutations are going to be equally responsive to the same targeted therapies, that all of the abnormalities are the same and react the same, and they really don't. We're really diving down and carving that pie thinner and thinner in terms of each individual MET abnormality, in terms of what drugs responds it to and what that means for patient outcomes and prognosis.” TS 25:21

"Lets Go Fly a KITE....And DOG Fight Coded messages!"Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe Gibsonwww.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/age-of-ashes-the-elven-portal-podcast--4189253/support.

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro share how You can improve your handling of "Aerial Service" as a goalkeeper. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

Interrogating a prisoner with a Champion around the corner or....Purchase Fantasy GroundsProducts through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe Gibsonwww.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, Feywild, Windswept plainsUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/age-of-ashes-the-elven-portal-podcast--4189253/support.

After A Week Off (Thanks All For Sharing Your Well Wishes Regarding The Union Staff Member) We are back! The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro share how You can become a better goalkeeper coach. Great listen for young coaches! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

With 1 named boss standing its time for back to back action!Purchase Fantasy Grounds Products through Our Affiliate link below. Roll Monger-Fantasy Groundshttp://affiliates.fantasygrounds.com/370352/15958Cast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe Gibsonwww.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/age-of-ashes-the-elven-portal-podcast--4189253/support.

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro explore some common misconceptions on goalkeepers and how we can change that narrative.   Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

A tenatious foe has his what crushed?Purchase Fantasy Grounds Products through Our Affiliate link below. Roll Monger-Fantasy GroundsCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe Gibsonwww.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/age-of-ashes-the-elven-portal-podcast--4189253/support.

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro share some tips on how you can become a more well rounded goalkeeper and not just a shot stopper.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss whether goalkeepers really need to go "D1" and why environment is more important than division.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

"Gnuros" Frog form is still the biggest baddest boss on the board!Purchase Fantasy Grounds Products through Our Affiliate link below. Roll Monger-Fantasy GroundsCast:-Host/GM Jeff Ball -PlayersMatt WittRyan MessinaDoug Baldwin-Extended Cameos byAndrew MalBurgJoesph DavisJoe Gibsonwww.RollMonger.comwww.TeeSpring.com/RollMongers for Merch!www.Patreon.com/RollMongersFind us with Alll the top rated Podcasts here on FeedSpotMusic: (Evan King) Intro/Outro: "Singularity"Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b..."Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Too Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildMedevil Town,Cathedreal,Tavern Celebraton,Castle jail, Waterkeep, Desert Winds, Escape From Shadow, Black Rider, Tavern Music,Halfling Sneak,Blacksmith Shop, Forest Night,Raven Puff,Whispering Caverns, Country Village, Victorian Slums, Catacombs, ,Makai Symphony https://makai-symphony.bandcamp.com/a.... "Tafi Maradi"Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b...Kevin_MacLeod_-_Virtutes_InstrumentiVilon,Kevin_MacLeod_-_Sonatina,Kevin_MacLeod_-_Schmetterling,Kevin_MacLeod_-_Virtutes_InstrumentiVilon, Kevin_MacLeod_-_Trio_for_Piano_Violin_and_Viola, "Slow Heat" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Digya" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Kumasi Groove" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... "Monkoto" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 License http://creativecommons.org/licenses/b... Lee_Maddeford_-_12_-_Tki_with_Les_Gauchers_OrchestraToo Cool kevin macloud Tabletop audioTabletopaudio.com"Xiengi Nights" CyberBar, Castle jail, Super Hero, Volcano, Jungle ruins, Medevil Market,Hell Hound Alley, Halfling Sneak, mansion Night,WaterKeep Nights,ravenpuff Commons, Tavern Music, metropolis fanfare, Sun Dappled trail, Through The Woods,The Hearth Inn, FeywildUploaded to You Tube @ The Roll mongers Podcast network "Bond Theme" Tom Schlueter https://soundcloud.com/tomschlueter/j... https://www.youtube.com/channel/UCc2w.... Evan King -- www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongers Thank You For your needed Support! www.RollMonger.com www.TeeSpring.com/RollMongers for Merch! www.Patreon.com/RollMongersReserved Material: Reserved Material elements in this product include all elements designated as Reserved Material under the ORC License. To avoid confusion, such items include: All trademarks, registered trademarks, proper nouns (characters, deities, locations, etc., as well as all adjectives, names, titles, and descriptive terms derived from proper nouns), artworks, characters, dialogue, locations, organizations, plots, storylines, and trade dress.Expressly Designated Licensed Material: This product contains no Expressly Designated Licensed Material.PAIZO INC.Creative Directors • James Jacobs and Luis LozaDirector of Game Design • Jason BulmahnDirector of Visual Design • Sonja MorrisDirector of Game Development • Adam DaigleManaging Creative Director (Starfinder) • Thurston HillmanLead Developers • James Case and John ComptonSenior Developers • Jessica Catalan, Eleanor Ferron, and Jenny JarzabskiDevelopers • Bill Fischer, Michelle Y. Kim, Mike Kimmel, Dustin Knight, and Landon WinklerLead Designer (Games) • Joe PasiniOrganized Play Line Developers • Josh Foster and Shay SnowDesign Manager • Michael SayrePathfinder Lead Designer • Logan BonnerSenior Designer • Jason KeeleyDesigners • Joshua Birdsong and Ivis K. FlanaganManaging Editor • Patrick HurleyLead Editor • Avi KoolSenior Editors • Ianara Natividad, Solomon St. John, and Simone D. SalléEditors • Felix Dritz, Priscilla Lagares, Lynne M. Meyer, and Zac MoranConcept Art Director • Kent HamiltonArt Directors • Kyle Hunter and Adam VickSenior Graphic Designer • Emily CrowellGraphic Designer • Adriana GasperiProduction Designer • Danika WirchDirector of Brand Strategy • Mark MorelandPaizo CEO • Lisa StevensPresident • Jim ButlerChief Creative Officer • Erik MonaVice President of People & Culture • Maggie GallagherVice President of Sales & Operations • Mike WebbVice President of Technology • Rei KoController • William JorenbyAccountant • Pasha JurgBecome a supporter of this podcast: https://www.spreaker.com/podcast/age-of-ashes-the-elven-portal-podcast--4189253/support.

In today's episode, supported by Takeda, we had the pleasure of speaking with Ibrahim T. Aldoss, MD, and Elias Jabbour, MD, about the use of ponatinib (Iclusig) monotherapy after combination chemotherapy in patients with newly diagnosed Philadelphia chromosome–positive (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Aldoss is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Drs Aldoss and Jabbour discussed findings from a post hoc subgroup analysis of the phase 3 PhALLCON trial (NCT03589326) that support the use of ponatinib monotherapy following combination treatment with a TKI plus chemotherapy in patients with newly diagnosed Ph-positive ALL, safety considerations when using ponatinib in this patient population, and how findings from this subgroup analysis may affect transplantation rates in this disease.

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss the biggest "problems" with "modern goalkeepers", and how TKI's attempting to bring something different to the table.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology. In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including: •⁠  ⁠The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease. •⁠  ⁠Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options. •⁠  ⁠The importance of patient characteristics and IMDC risk categorization in treatment decisions. •⁠  ⁠Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects. •⁠  ⁠The role of ctDNA, PD-L1 testing, and NGS in RCC. Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients. YouTube: https://youtu.be/Bbv9N7-YKIM Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!  

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss the TKI "Apprenticeship" program and the benefits for young goalkeepers to work in an academy environment on and off the field.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro introduce the new TKI GK Coaching Course and breakdown some misconceptions about TKI. Great listen for young players and parents!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

Dr. Jyoti Patel is back on the podcast to discuss the updates to the living guideline on therapy for stage IV NSCLC with driver alterations. She shares updated recommendations in the first- and second-line settings for patients with stage IV NSCLC and classical EGFR mutations, and the impact of these updates for clinicians and patients. We also look to the future to discuss ongoing developments in the field. Read the full living guideline update “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3” at www.asco.org/living-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at http://www.asco.org/living-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO-24-02785     Brittany Harvey: Welcome to the ASCO Guidelines Podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges and advances in oncology. You can find all the shows including this one at asco.org/podcasts.   My name is Brittany Harvey and today I'm interviewing Dr. Jyoti Patel from Northwestern University, co-chair on “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3.” It's great to have you back on the show today, Dr. Patel. Dr. Jyoti Patel: Thanks so much. Happy to be here. Brittany Harvey: And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Patel, who has joined us here today, are available online with the publication of the guideline and in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content of this update, Dr. Patel, this clinical practice guideline for systemic therapy for patients with stage IV non small cell lung cancer with driver alterations is living, meaning that it's continuously reviewed and updated. So what data prompted this latest change to the recommendations? Dr. Jyoti Patel: Thanks so much. So it's really been an exciting time in the treatment of EGFR lung cancer, particularly this past year has required us to rethink approaches to front- and second-line therapy. In this particular update, we examined what patients in the front-line setting may be offered by their clinicians. And so we're talking about the population of classical EGFR mutations, so exon 19 and exon 21 L858R substitution. And so certainly for this population, osimertinib has a high level of evidence and should be offered to all patients at the time of diagnosis when they present with advanced disease. Our last update included a recommendation that patients could also get platinum doublet chemotherapy with osimertinib or osimertinib alone. This current recommendation also introduces another alternative therapy and that's the combination of amivantamab plus lazertinib. And so now, clinicians are faced with three really good options for their patients with EGFR exon19 deletion or L858R. Brittany Harvey: It's great to hear that there's this advance in the space, particularly for patients with these classical EGFR mutations that you mentioned. So what should clinicians know as they implement these new first-line recommendations? Dr. Jyoti Patel:  I think it's become more complex than ever. Certainly, we know again that patients should get osimertinib in the frontline setting. But we've been kind of stuck at progression-free survival that's between a year and a half and two years. And so we've really been looking at opportunities to intensify therapy. So one could certainly be with chemotherapy or switching over to amivantamab, the bispecific antibody that targets EGFR and MET plus lazertinib, an oral TKI that's very similar in structure to osimertinib. And when you're talking to a patient, it's really a conversation about balancing efficacy with toxicity. Unfortunately, as we know, there aren't that many free lunches. And so if we think about what a patient is hoping for in their therapy and how we can further personalize treatment options, really is important to look at some of the analyses for this study. So in the study of amivantamab plus lazertinib, we know that there were increased toxicities with a combination of both therapies. In fact, up to 75% of patients had over grade 3 toxicities, versus about 43% of patients with osimertinib monotherapy. And we know if we look back at FLAURA2, almost two thirds of patients with osimertinib and chemotherapy had grade 3 toxicities, compared to 27% of patients with osimertinib alone. So we certainly see an increase in toxicities. Then we have to ask ourselves, are those paper toxicities or ones that really impact patients? And we know that amivantamab, for example, causes significant cutaneous toxicities. With both of these therapies, whether it's chemotherapy or adding amivantamab, there's the burden of infusional visits and increased time in the doctor's office. Certainly with chemotherapy, there can be an increased incidence of myelosuppression. And so when we're thinking about advising our patients, certainly we need to talk about the toxicities. But one thing that we've been able to do is to look at the patients that were included in this trial. And what we really find is that in higher risk cohorts, particularly those that we know historically have done less well with standard osimertinib, so patients, for example, with CNS metastasis, for those patients with co-mutations, it may be that that additive benefit is significant. And so one example I think would be from the MARIPOSA study, again, the study of amivantamab and lazertinib versus chemotherapy. What we can say is that patients who had co-mutations, so patients with EGFR mutations as well as TP53, lazertinib and amivantamab led to a hazard ratio of 0.65 compared to osimertinib alone. So that was 18.2 months versus 12.9 months. And so this may be really important to patients. And we also see conversely that patients with wild type TP53, so those patients who didn't have the mutation, probably had equivalent survival regardless of therapy. So certainly, we need to prospectively study some of these high-risk cohorts. We've only seen progression-free survival in these studies. And so at this juncture, we can advise our patients about toxicity, the improvements in certain categories of progression-free survival, but we really still don't know how this pans out in overall survival. In many of these studies, all patients do not necessarily cross over to the study arm and so they may have lost the benefit of subsequent therapy. Brittany Harvey: Absolutely. It's very important to talk about that balance of benefits and risks and particularly those toxicities that you discussed. So I appreciate reviewing that recommendation and the considerations for clinicians for first-line therapy. This update also included a second-line treatment update. What is that update for patients with EGFR alterations? Dr. Jyoti Patel: So this is where it gets super tricky because we have a frontline option with amivantamab and now we've had an update in the second line option. So what we said is that for patients who have progressed on an EGFR TKI, and in the United States, certainly that's predominantly osimertinib, or those in other parts of the world that may have gotten an earlier generation TKI, but do not have evidence of T790M or other targetable mutations, we can offer patients chemotherapy with or without amivantamab. And so certainly we have seen that this again leads to improved survival. There have also been a number of studies looking at incorporation of PD-L1 and anti-VEGF therapies. And what we can say, I think pretty clearly is that multiple phase 3 trials have really shown no benefit of the addition of PD-1 to platinum chemotherapy. But there are some emerging bispecific antibodies that may target PD-1 as well as VEGF, or combinations of antibodies that target both of those pathways that may improve outcome. At this juncture, I think we feel that the evidence surrounding chemotherapy plus amivantamab is strongest, but there is certainly work in this space that will be of interest. Now, what happens if your patient received amivantamab and lazertinib in the frontline setting and then has progression? And so we're trying to understand resistance mechanisms and opportunities for treatment. What the panel decided to recommend, based on the available evidence, was that certainly those patients should get platinum-based chemotherapy, but there may also be a role for antivascular endothelial growth factor targeting therapy such as bevacizumab in patients in whom it would be safe. Brittany Harvey: Great. I appreciate you detailing those recommendations when it gets complicated in the second-line setting. So what should clinicians know as they implement these second-line recommendations too? Dr. Jyoti Patel: So certainly the frontline setting matters significantly. So if a patient gets osimertinib in the frontline setting, we generally suggest that patients undergo repeat testing to see if they have another targetable mutation. If they don't, then I think preferred therapy would be chemotherapy with or without amivantamab. And amivantamab leads to a significant improvement in progression-free survival and response rate at the cost of increased risk of toxicity. For patients who get FLAURA2 in the frontline setting, chemotherapy plus osimertinib, it's a little bit of an unclear space. Those patients most likely would get docetaxel with or without ramucirumab. But there are other agents that we hope to have available to our patients in the near future. For patients who receive amivantamab and osimertinib, we recommend that those patients get chemotherapy probably with anti-VEGF as demonstrated by multiple trials that have shown the improved progression-free survival with introduction of an anti-VEGF agent. And we've seen evidence of amivantamab in the third line setting, so it is likely that this question about sequencing really takes center stage in our next set of trials. When you're talking to a patient, I think again, it's absolutely important to discuss: What are their goals? How symptomatic or how fast is their progression? Are there ways in which patients may benefit from spot treatment oligoprogression such as radiation? When is the right time for introduction of amivantamab and when do we think patients need chemotherapy? Is it up front or predominantly in the second-line setting? Brittany Harvey: Definitely. And then you've just touched on the goals of treatment for individual patients. So in your view, what does this update mean for patients with stage IV non-small cell lung cancer and an EGFR alteration? Dr. Jyoti Patel: For patients, this is a time in which shared decision making really needs to take center stage. So our best patients are those patients that are best informed not only about their disease but also have a good understanding about what is important to them and their families in terms of care. And so bringing that shared understanding to the table again helps us think about this particular cancer as more of a journey rather than just a one off treatment. Therapy will hopefully be prolonged, and so it's absolutely important that we address toxicities, make therapies more tolerable, again, with the shared goal of living long and living well. Brittany Harvey: Absolutely. Those are key points to making sure that patients are living both longer and have a good quality of life during that time as well. So then, before you mentioned the possibility of future sequencing trials and other ongoing developments. What additional studies or future directions is the panel examining for future updates to this living guideline? Dr. Jyoti Patel: So certainly we're thinking about trials that look at, for example, cfDNA clearance. So are there patients that do well and can we detect that early on without having to intensify therapy on day 1 so it may be that we add chemotherapy a little bit later. I think really exciting are some of the new bispecific. The HARMONi-A trial was a trial in China of a novel bispecific, ivonescimab. And this drug targets both PD-1 and VEGF and it was combined with chemotherapy. And this trial found almost a doubling of progression-free survival with this drug in combination chemotherapy in an EGFR patient population. That study is being planned and being run in the United States to see if we have similar outcomes with a more diverse population. So certainly that's exciting. There are a number of antibody drug conjugates that are being studied in the post-chemotherapy setting as well. And I think we'll likely soon see a better understanding of what co-mutations and burden of disease really mean when we're thinking about assigning treatment. So which patients, again, need intensification of therapy and which patients may do really well on just an oral agent that they're taking at home with more tolerable toxicity than dual treatment. Brittany Harvey: Yes, we'll look forward to continued developments in these fields and seeing some of those studies come to fruition. So with that, I want to thank you for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Patel. Dr. Jyoti Patel: Thanks so much, Brittany. It's really an exciting time for lung cancer and we hope that these updates really help physicians decide the best treatments for their patients. Again, it's a rapidly evolving landscape which is fantastic, but it does become more cumbersome to stay ahead of the literature. Brittany Harvey: Definitely. And so we appreciate your time and the panel's time spent reviewing this literature and providing this much needed information to clinicians everywhere. So finally, thank you to all of our listeners for tuning into the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/living-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the  Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod TKI Star Coaches Tori Corsaro & Kieran Burns share how goalkeepers can learn to dominate their half-space by breaking down some match actions in NWSL & The EPL from world class GK's! Great listen for players, parents, and coaches as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro break down some match scenarios and share 3 tips to turn your shot prevention into quality actions! Great listen for players, parents, and coaches as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss the concept of "potential" and why many times the narrative is wrong!  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro review the successful TKI San Diego Camps & Clinics, and why it's important for Professional Goalkeepers to give back to the community.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro are joined by another Strength and Conditioning Expert Leah Brady! They discuss EVERYTHING a young goalkeeper needs to know about Sports Performance.  Great listen for players and parents as well!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss how to normalize certain habits for youth goalkeepers in your training environment.   Great listen for players looking to embark on a pro career!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is an episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod Former USWNT GK & Current NWSL Analyst Jill Loyden and Strength & Conditioning Guru Tori Corsaro discuss how to breakdown your 4 main "wins" as a goalkeeper in 2024 and how to use those to continue your development in 2025.  Great listen for players looking to embark on a pro career!  Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises

The Following is a "Hall of Fame"  episode of the highly acclaimed TKI podcast now exclusively on the Union GK Podcast Network every Wed & Friday! On Today's Pod, TKI Strength & Conditioning Coach Tori Corsaro and Former USWNT GK Jill Loyden share some tips for youth goalkeepers during club tryouts.  Share your feedback. Not one to miss for players and parents! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises